Bio-Path (BPTH) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Conference overview

• H.C. Wainwright hosted a global investment conference with presentations from companies across sectors.

• Bio-Path Holdings presented its clinical pipeline and technology advancements.

Technology and pipeline highlights

• DNAbilize technology enables targeted, systemic delivery of antisense oligonucleotides with no observed toxicity in human trials.

• The platform supports multiple drug candidates, each targeting different oncology indications.

Clinical trial updates and results

• Phase 2 AML trial for prexigebersen showed 75% complete remission in newly diagnosed and 55% in relapsed/refractory patients, both higher than historical controls.

• BP1001-A in solid tumors demonstrated tumor reduction and improved quality of life at higher doses.

• BP1002 is advancing in Phase 1 trials for lymphoma, CLL, and relapsed/refractory AML, with FDA approval to proceed to higher dose cohorts.

• BP1003, targeting STAT3, is completing IND studies for a planned Phase 1 trial in refractory metastatic solid tumors.